Drug-diet interactions in the treatment of mental illness are reviewed from two perspectives: the potential effects of drugs on a person's nutritional status, and the effect of diet on drug action through modification of its absorption or various stages of its metabolism. As mental illness is often chronic and recurrent, requiring long-term drug therapy, it is important to become aware of the effects of drugs and their possible interactions with other important factors such as food.
References
1.
KalantO.J.The amphetamines: toxicity and addiction.Toronto: Toronto University Press, 1973.
2.
BradleyC.The behaviour of children receiving benzedrine.Am J Psychiatry1937; 94: 577–674.
3.
SaferD., AllanR., BarrE.Depression of growth in hyperactive children on stimulant drugs.N Engl J Med1972; 287: 217–20.
4.
SaferD., AllanR., BarrE.Growth rebound after termination of stimulant drugs.J Pediatr1975; 86: 113–8.
5.
GrossM.D.Growth of hyperkinetic children taking methylphenidate, dextroamphetamine or imipramine/desipramine.Pediatrics1976; 58: 423–31.
6.
GreenblattD.J., ShaderR.I.Benzodiazepines in clinical practice.Raven Press, New York: 1974.
7.
PaykelE.S., MuellerP.S., De La VergneP.M.Amitriptyline, weight gain and carbohydrate craving: a side effect.Br J Psychiatry1973; 122: 482.
8.
SinghM.M., DiosL.V., KlineN.S.Weight as a correlate of clinical response to psychotropic drugs.Psychosomatics1970; 11: 562–70.
9.
DempseyM., DunnerD.L., FieveR.R.Treatment of excessive weight gain in patients taking lithium.Am J Psychiatry1976; 133: 1082–4.
10.
PiepaoliP.G.Drug therapy and diet.Drug Intell Clin Pharm1972; 6: 89.
11.
GottfriesC.G.Influence of depression and antidepressants on weight. In recent advances in the treatment of depression.Acta Psychiatr Scand1981; 63(Suppl. 290): 353–6.
12.
GardosG., ColeJ.O.Weight reduction in schizophrenics by molindone.Am J Psychiatry1977; 134: 302–4.
13.
CarsonJ.A.S., GormicanA.Disease-medication relationships in altered taste sensitivity.J Am Diet Assoc1976; 68: 550–3.
14.
US National Research Council, Sub-Committee on Zinc: Zinc.Baltimore, MD.: University Park Press, 1979.
15.
GarfinkelP., MoldofskyH., GarnerD.M.The heterogeneity of anorexia nervosa.Arch Gen Psychiatry1980; 37: 1036–40.
16.
Rivera-CalimlimL.Effect of lithium on gastric emptying and absorption of oral chlorpromazine.Psychopharmacol Commun1976; 2: 263–72.
17.
EhrlichB.E., DiamondJ.M.Lithium absorption: implications for sustained release preparations.Lancet1983; 1: 306.
18.
FaloonW.W.Drug production of intestinal malabsorption.NY State J Med1970; 70: 2189–93.
19.
MarchD.C.Handbook: interactions of selected drugs with nutritional status in man.Chicago: American Dietetic Association, 1976.
20.
RoeD.A.Drug-induced nutritional deficiencies.Westport, Connecticut: Ari Publishing1976: 211.
21.
LamyP.P.Effects of diet and nutrition on drug therapy.J Am Ger Soc (Supplement)1982; 30: S99–112.
22.
GranerusA., JogenburgR., RogersS.Inhibition of 1-phenylalanine absorption in patients treated with L-dopa for Parkinsonism.Proc Soc Exp Biol Med1971; 137: 942–5.
23.
DentC.E., RichensA., RoweD.J.F., StampT.C.B.Osteomalacia with long-term anticonvulsant therapy in epilepsy.Br Med J1970; 4: 69–73.
24.
BorgstedtA.D., BrysonM.F., YoungL.W., ForbesG.B.Long-term administration of antiepileptic drugs and the development of rickets.J Pediatr1972; 81: 9–15.
25.
LaderM.Introduction to psychopharmacology.Michigan: Scope Publication, 1980: 81.
26.
HartshornE.A.Handbook of drug interactions, 2nd ed.Hamilton, Ill: Drug Intelligence, 1973: 133.
27.
KosterM., DavidG.K.Reversible severe hypertension due to licorice ingestion.N Engl J Med1968; 278: 1381–3.
28.
WinsteadD.K.Coffee consumption among psychiatric inpatients.Am J Psychiatry1976; 133: 1447–50.
29.
LaderM.Monitoring plasma concentrations of neuroleptics.Pharmakopsychiatric1976; 9: 170–7.
30.
KulhanekF., LindeO.K., MeisenbergG.Precipitation of antipsychotic drugs in interaction with coffee or tea.Lancet1979; 2: 1130.
31.
MikkelsenE.J.Caffeine and schizophrenia.J Clin Psychiat1978; 39: 732–5.
32.
McLeanA.J.Food, splanchnic blood flow and bio-availability of drugs subject to first-pass metabolism.Clin Pharmacol Ther1978; 24: 5–10.
33.
MisraD.P., LoudonJ.M., StaddonG.E.Albumin metabolism in elderly patients.J Gerontol1975; 30: 304–6.
34.
Compendium of pharmaceuticals and specialties.Canadian Pharmaceutical Assoc., Ottawa, 1982: 528.
35.
MenaI., CotziasG.C.Protein intake and treatment of Parkinson's disease with levodopa.N Engl J Med1975; 292: 181–5.
36.
MaksH.Levodopa, carbidopa and pyridoxine in Parkinson's disease.Arch Neurol1974; 30: 444–8.
37.
YahrM.D., DuvoisinR.Pyridoxine, levodopa and methyldopa hydralzide regimen in Parkinsonism.JAMA1971; 216: 2141–3.
38.
PowellM.F., LamyP.P.Drug-dietary incompatibilities — effects on drug therapy.Hosp Formul1977; 12: 870–4.
39.
ThomsenK., SchouM.Renal lithium excretion in man.Am J Physiol1968; 215: 823–7.
40.
SingerI., ForrestJ.N.Drug-induced states of nephrogenic diabetes insipidus.Kidney Int1976; 10: 82–95.
41.
UldallP.R., AwadA.G., McCormickW.O.Renal function in patients receiving long-term lithium therapy.Can Med Assoc J1981; 124: 1471–4.
